How Blue Cross Blue Shield’s 2025 formulary updates handle Zepbound after FDA’s new cardiovascular risk-reduction indication approval

How Blue Cross Blue Shield’s 2025 formulary updates handle Zepbound after FDA’s new cardiovascular risk-reduction indication approval

Blue Cross Blue Shield (BCBS) plans are reshaping their 2025 formularies to reflect one of the most impactful regulatory updates in metabolic and cardiovascular medicine this year. After the U.S. Food and Drug Administration (FDA) approved Zepbound (tirzepatide) for reducing cardiovascular risk in adults with obesity and known heart disease, several BCBS plans moved fast to reclassify how the drug fits into their benefit structures. The result: meaningful ripple effects for patients, prescribers, and the administrators who have to sort through tier placement and prior-authorization rules.

Background: Zepbound’s path and the new indication

Zepbound, from Eli Lilly and Company, received its first FDA nod in November 2023 for chronic weight management in adults with obesity or overweight plus a weight-related condition such as hypertension, dyslipidemia, or type 2 diabetes. It’s a dual GIP and GLP-1 receptor agonist, the same ingredient Lilly markets as Mounjaro for type 2 diabetes.

Then in March 2024, the FDA expanded Zepbound’s label to reduce major adverse cardiovascular events (MACE) in adults with obesity and established cardiovascular disease. That placed it alongside Wegovy (semaglutide), which gained the same cardiovascular claim that same month. For payers, this matters a lot because most plans still separate pure weight-loss therapies from drugs used to prevent repeat cardiac events. Coverage logic changes once a drug crosses that clinical line.

How Blue Cross Blue Shield organizations structure formulary decisions

BCBS is technically a federation, 33 independent companies covering around 115 million Americans under the umbrella of the Blue Cross Blue Shield Association (BCBSA). Each regional plan makes its own calls about coverage, but the BCBSA issues recommended frameworks. For 2025, that guidance came out in August 2024, a few months after the FDA label expansion. Most affiliates review those recommendations in late summer and lock in final versions by the end of the year.

Here’s how the tiers usually line up in BCBS formularies:

What’s shifting for Zepbound in 2025

Under the 2025 National Preferred Formulary, BCBSA still lists Zepbound as a Tier 3 non-preferred brand. Prior authorization remains standard. But the cardiovascular indication is changing how that plays out in practice. Many regional plans now include a second approval track: if the prescription links to documented cardiovascular disease and meets clinical criteria, authorization gets waived or auto-approved.

Example: Blue Cross Blue Shield of Massachusetts announced that starting January 1, 2025, Zepbound stays Tier 3 for weight management but moves to Tier 2 for members with ICD-10 codes for atherosclerotic cardiovascular disease (ASCVD), prior heart attack, or heart failure with reduced ejection fraction. That’s the same split treatment Wegovy adopted in 2024 after its CV claim.

Over on the West Coast, Blue Shield of California’s 2025 formulary adds a “CV indication access” path across certain employer groups. When prescribers tag the cardiovascular use and provide the related documentation, authorization gets bypassed. A technical solution, really, but it makes an enormous administrative difference.

Comparing Zepbound with other GLP-1-based drugs

Wegovy (semaglutide from Novo Nordisk) remains Zepbound’s main competition. Both now have cardiovascular labels, but BCBS payers notice the cost spread. 2024 CMS Medicare Part D data showed list pricing at roughly $1,060 for tirzepatide 10 mg versus $1,349 for semaglutide 2.4 mg per month. Plan discounts and rebates blur that, but still, Lilly’s lower WAC price gives BCBS drug committees a reason to push for parity coverage or better rebates.

Below is a snapshot of how major BCBS commercial plans are categorizing GLP-1 drugs for 2025, based on InsureWith.ai filings from October 2024.

Employer and plan sponsor considerations

Employers are rethinking how to structure benefits for GLP-1 drugs now that they affect both weight and cardiovascular outcomes. According to the KFF Employer Health Benefits Survey, about 22% of large employers covered some form of weight-loss medication in 2023. That number jumped to 47% by mid-2024 once the FDA added heart-related indications. In other words, the “lifestyle drug” narrative ended fast.

For 2025, fully insured BCBS clients automatically inherit the new formulary rules. Self-funded employers, the ones using BCBS as administrator, still get to decide what they want to exclude or tweak. Benefits managers will be busy comparing how each Pharmacy Benefit Manager (PBM) interprets the cardiovascular carve-out. OptumRx and Prime Therapeutics, the two PBMs most tied to BCBS, have already started broad-scale implementation.

Expect scrutiny. Pharmacy committees project a 30-40% jump in prior-authorization volume for GLP-1 drugs early in 2025. And yes, plenty of members will try to switch from Wegovy to Zepbound if it lands in the cheaper tier tied to a cardiovascular code. That’s not theory; it’s already showing up in utilization data drafts I’ve seen.

Impact on patients

For patients prescribed Zepbound purely for obesity, coverage still looks tough. Tier 3 coinsurance at 50% often pushes patient cost above $500 a month depending on negotiated discounts. When doctors list the cardiovascular indication and the plan shifts it to Tier 2, those numbers often drop to $75-$120. A huge difference for adherence.

Utilization patterns are also shifting. IQVIA data show a 60% year-over-year surge in GLP-1 prescriptions through mid-2024, with a growing share tagged for cardiovascular prevention rather than weight control. BCBS actuaries assume that curve will keep climbing. A few plans already added dosage limits and refill timing checks, basically to contain off-label overuse.

Pharmacy considerations and dispensing challenges

Pharmacists serving BCBS members need to double-check indication coding before claim submission. Coverage hinges on the ICD-10 codes attached to the prescription. BCBS systems now flag cardiovascular-coded claims and automatically skip step therapy edits. Until every chain and PBM syncs their 2025 templates, pharmacists might need manual overrides. That gets tedious. But better than rejected claims.

Specialty pharmacies under Accredo and Kroger report processing times improving roughly 20% post-integration of indication-based automation. That speeds things up but raises the stakes for data accuracy. One wrong code, and the claim bounces. Look, nobody loves debugging pharmacy software, but these workflows matter, especially when patients can’t afford a delay.

Regulatory outlook and what it means long term

CMS still bars Medicare Part D from paying for drugs labeled for weight loss. The cardiovascular evidence is forcing some rethinking, though. BCBS affiliates have already asked CMS to carve out exceptions for drugs like Zepbound that show hard outcomes data. So far, no movement. Medicare Advantage plans tied to BCBS remain stuck excluding it, unless they add it as a supplemental benefit or inside a trial.

The commercial side isn’t waiting. Insurers now treat GLP-1s as chronic disease tools, not cosmetic options. The 2025 BCBS formulary makes that official. Zepbound’s revised access rules show how quickly a well-documented label change can rewrite benefit logic inside a payer network. There’s probably more to come, but that’s a conversation for another post.

Medical and Insurance Disclaimer: This content is for informational purposes only and does not provide medical advice. Coverage terms vary among regional Blue Cross Blue Shield plans. Always verify individual plan benefits, prior-authorization rules, and pharmacy network restrictions before prescribing or dispensing any medication.